Dallas – It’s not as routine as having your teeth cleaned, but a growing number of people are going to hospitals to get their heart arteries unclogged and going home the same day.
New research presented by Canadian researchers Sunday at an American Heart Association conference suggests that a new approach to angioplasty makes it safe to send patients home the same day. Complications were no greater for those who went home a few hours afterward than for those who were hospitalized overnight.
“This is the kind of study that’s going to turn the trend” and get more doctors to try it, said Dr. Timothy Gardner, a Delaware cardiologist who heads the meeting committee but did not have a role in the research.
Angioplasty is one of the most common medical techniques in the world. About 600,000 are done each year in the United States alone.
Through an artery in the leg near the groin, doctors snake a tube to blockages that are clogging vessels and preventing them from supplying enough blood to the heart. A tiny balloon is inflated to flatten the blockage, and a mesh scaffold called a stent is left behind to prop the artery open.
Two kinds of complications can occur: bleeding from the leg incision and reclogging of the heart artery.
To avoid the first problem, Canadian researchers led by Dr. Olivier Bertrand of Laval Hospital Research Center in Quebec did angioplasty a different way, using an artery in the arm near the wrist instead of one in the leg, which greatly reduced bleeding.
Next, they tested the need to keep patients overnight by giving half the patients in their study a single dose of anti-clotting medication and sending them home four to six hours afterward. The other half got standard treatment: the single dose plus a 12-hour intravenous one given overnight in the hospital.
Six months later, the rates of major bleeding, heart attacks or need for repeat procedures to treat blockages were nearly identical in the two groups: 30 among the 504 patients given the single drug dose versus 28 in the other 501 patients.
The combination of arm angioplasty and single-dose drug treatment “is extremely safe,” Bertrand said.
The study was funded by Eli Lilly and Co., Bristol-Myers Squibb and Sanofi-Aventis, makers of ReoPro, the anti-clotting drug used in the experiment. Bertrand said he had no financial ties to any of the companies.
Outpatient angioplasty is common in France, Japan, Canada, Germany, much of South America and Australia, and is growing in popularity around the United States.
